Snap-8, marketed under the INCI name acetyl octapeptide-3 (also acetyl glutamyl heptapeptide-1), is a synthetic 8-amino-acid peptide developed as a topical neurocosmetic. It is structurally derived from and functionally related to Argireline (acetyl hexapeptide-8), with two additional amino acids that researchers report enhance binding affinity at the SNARE complex. Its mechanism targets the molecular machinery of neuromuscular transmission — specifically the SNAP-25 protein — through competitive peptide mimicry rather than enzymatic cleavage.
Snap-8 is an N-acetylated octapeptide amide: Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2.
Molecular formula: C42H72N16O15S. Molecular weight: 1,073.2 g/mol. INCI name: acetyl octapeptide-3. CAS: 868844-74-0. Classification: topical SNARE-targeting peptide; neurocosmetic.
The sequence mimics the N-terminal region of SNAP-25. C-terminal amidation improves formulation stability versus a free carboxyl terminus.
Neuromuscular contraction requires the SNARE complex — proteins (SNAP-25, syntaxin, synaptobrevin) that mediate synaptic vesicle docking and acetylcholine release. Botulinum toxin cleaves SNAP-25 irreversibly. Snap-8 operates by competitive peptide mimicry: its sequence resembles the N-terminal domain of SNAP-25, allowing it to compete for binding sites within the SNARE complex, reducing (but not eliminating) acetylcholine release and attenuating muscle contraction at treated areas.
Result: reversible, concentration-dependent softening of dynamic expression wrinkles rather than full paralysis. Snap-8 is topically delivered and does not enter systemic circulation at meaningful concentrations when applied topically.
28-Day Topical Efficacy Study (Lipotec, manufacturer data): 17 women applying 10% Snap-8 solution twice daily for 28 days showed mean wrinkle depth reduction of 34.98%, compared to approximately 27.05% for 10% Argireline under similar conditions. Maximum reductions reached 62–63% in individual subjects. Tolerability rated excellent; no significant adverse events reported.
Comparison with Argireline: The two additional amino acids in Snap-8 versus Argireline are reported to enhance SNAP-25 binding affinity, producing approximately 30% greater wrinkle reduction at equivalent concentrations in short-term topical use.
Snap-8 is studied in: cosmetic peptide pharmacology, SNARE complex biology, topical neurocosmetic formulation science, comparative anti-wrinkle peptide efficacy, and dermatological delivery systems including microneedle arrays.
Additional research contexts include comparative studies against acetyl hexapeptide-8 (Argireline) and other SNARE-modulating peptides, evaluation of penetration enhancers such as liposomal and ethosomal carriers, stability testing across cosmetic emulsion systems, and structure-activity relationship studies exploring how N-terminal acetylation and C-terminal amidation influence peptide half-life and binding kinetics at the SNAP-25 interface. Investigators also use Snap-8 as a reference peptide when benchmarking novel neurocosmetic candidates in in-vitro neuromuscular junction models and reconstituted SNARE assembly assays. Formulation scientists further explore compatibility with hyaluronic acid matrices, silicone elastomer gels, and anhydrous serum bases to optimize topical bioavailability.
Form: lyophilized powder. Purity: ≥98% HPLC verified. Storage: 2–8°C short-term; −20°C long-term, away from light. Application: topical research use only — this compound is not for injection.
For research use only. Not for human consumption.
Snap-8 is an octapeptide; Argireline is a hexapeptide. Snap-8 has two additional amino acids (Ala and Asp) that increase SNAP-25 binding affinity, producing greater competitive inhibition of SNARE complex formation at equivalent doses.
A 28-day study of 17 subjects applying 10% Snap-8 twice daily showed a mean 34.98% reduction in wrinkle depth, with maximum reductions approaching 63%.
Manufacturer and published cosmetic data report excellent tolerability for topical Snap-8 at concentrations up to 10%. It is not approved for injectable use.
The SNARE (soluble NSF attachment protein receptor) complex is the molecular machinery that mediates synaptic vesicle docking and neurotransmitter release at the neuromuscular junction. SNAP-25 is a key component of this complex.